Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY.

Presentation: Wednesday, June 3, 2026 at 9:55am – 10:25 am ET

A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

Media & Investor Contacts:
Carl Mauch
[email protected]

You May Also Be Interested In

• Gold Exchange Universe Launches Portal Version 24k — Sydney’s Precious Metal Buyers for Scrap Gold, Gold Bullion and Jewellery, Paying Close to 98% of Spot
• WOLF777 Announces Enhanced Login Security Initiative to Support Faster and Safer Account Access
• Bonk Price Prediction Eyes July Bounce as AlphaPepe CEX-Watch Buzz Drives Pre-Chart Demand